rF1V
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $84,247 | 382 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $84,247 | 382 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 2, randomized, active-controlled, observer-blind, multicenter trial of the immunogenicity, safety and tolerability of rF1V vaccine with CpG 1018 adjuvant compared with rF1V vaccine alone in approximately 200 healthy volunteers between the ages of 18 and 55 years of age | Dynavax Technologies Corporation | $84,247 | 0 |
Top Doctors Receiving Payments for rF1V
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Melbourne, FL | $84,247 | 382 |
Manufacturing Companies
- Dynavax Technologies Corporation $84,247
Product Information
- Type Drug
- Total Payments $84,247
- Total Doctors 0
- Transactions 382
About rF1V
rF1V is a drug associated with $84,247 in payments to 0 healthcare providers, recorded across 382 transactions in the CMS Open Payments database. The primary manufacturer is Dynavax Technologies Corporation.
Payment data is available from 2024 to 2024. In 2024, $84,247 was paid across 382 transactions to 0 doctors.
The most common payment nature for rF1V is "Unspecified" ($84,247, 100.0% of total).
rF1V is associated with 1 research study, including "A Phase 2, randomized, active-controlled, observer-blind, multicenter trial of the immunogenicity, safety and tolerability of rF1V vaccine with CpG 1018 adjuvant compared with rF1V vaccine alone in approximately 200 healthy volunteers between the ages of 18 and 55 years of age" ($84,247).